CA2692632A1 - Procedes et compositions de traitement du cancer et d'autres maladies associees a l'angiogenese - Google Patents

Procedes et compositions de traitement du cancer et d'autres maladies associees a l'angiogenese Download PDF

Info

Publication number
CA2692632A1
CA2692632A1 CA 2692632 CA2692632A CA2692632A1 CA 2692632 A1 CA2692632 A1 CA 2692632A1 CA 2692632 CA2692632 CA 2692632 CA 2692632 A CA2692632 A CA 2692632A CA 2692632 A1 CA2692632 A1 CA 2692632A1
Authority
CA
Canada
Prior art keywords
ang
sirna
nucleic acid
expression
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2692632
Other languages
English (en)
Inventor
Frank Y Xie
Xiaodong Yang
Yijia Liu
Qing Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Silence Therapeutics PLC
Original Assignee
Intradigm Corporation
Frank Y Xie
Xiaodong Yang
Yijia Liu
Qing Zhou
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intradigm Corporation, Frank Y Xie, Xiaodong Yang, Yijia Liu, Qing Zhou filed Critical Intradigm Corporation
Publication of CA2692632A1 publication Critical patent/CA2692632A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA 2692632 2007-07-06 2008-07-03 Procedes et compositions de traitement du cancer et d'autres maladies associees a l'angiogenese Abandoned CA2692632A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US95851907P 2007-07-06 2007-07-06
US60/958,519 2007-07-06
US96608507P 2007-08-24 2007-08-24
US60/966,085 2007-08-24
US13187608P 2008-06-12 2008-06-12
US61/131,876 2008-06-12
PCT/US2008/008232 WO2009008990A2 (fr) 2007-07-06 2008-07-03 Procédés et compositions de traitement du cancer et d'autres maladies associées à l'angiogenèse

Publications (1)

Publication Number Publication Date
CA2692632A1 true CA2692632A1 (fr) 2009-01-15

Family

ID=40229333

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2692632 Abandoned CA2692632A1 (fr) 2007-07-06 2008-07-03 Procedes et compositions de traitement du cancer et d'autres maladies associees a l'angiogenese

Country Status (6)

Country Link
US (1) US20110015249A1 (fr)
EP (1) EP2170351A4 (fr)
JP (1) JP2010532662A (fr)
CN (1) CN101959521A (fr)
CA (1) CA2692632A1 (fr)
WO (1) WO2009008990A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2398903A1 (fr) * 2009-02-18 2011-12-28 Silence Therapeutics Aktiengesellschaft Moyen d'inhibition de l'expression de ang2
US9096643B2 (en) * 2010-08-27 2015-08-04 Milica Radisic Cell-protective peptides and uses thereof
SG189280A1 (en) * 2010-10-07 2013-05-31 Agency Science Tech & Res Parp-1 inhibitors
GB201102283D0 (en) * 2011-02-09 2011-03-23 Ucl Business Plc Treatment
WO2017134526A1 (fr) * 2016-02-02 2017-08-10 Olix Pharmaceuticals, Inc. Traitement de maladies associées à l'angiogenèse au moyen de complexes d'arn ciblant angpt2 et pdgfb
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents
CN108888756A (zh) * 2018-07-25 2018-11-27 韩曙 C16多肽和血管生成素Ang1的应用和应用二者的药物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
WO1999042091A2 (fr) * 1998-02-19 1999-08-26 Massachusetts Institute Of Technology Compositions d'apport dans des cellules
WO2001047496A1 (fr) * 1999-12-29 2001-07-05 Mixson A James Copolymere d'histidine et procedes d'utilisation associes
US20050159380A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of angiopoietin gene expression using short interfering nucleic acid (siNA)
US7081443B2 (en) * 2002-05-21 2006-07-25 Korea Advanced Institutes Of Science And Technology (Kaist) Chimeric comp-ang1 molecule
US20040115640A1 (en) * 2002-12-11 2004-06-17 Isis Pharmaceuticals Inc. Modulation of angiopoietin-2 expression
US20060211637A1 (en) * 2002-08-06 2006-09-21 Intradigm Corporation Methods of down regulating target gene expression in vivo by introduction of interfering rna
WO2006006948A2 (fr) * 2002-11-14 2006-01-19 Dharmacon, Inc. Methodes et compositions permettant de selectionner des arnsi presentant une fonctionnalite amelioree
CA2522730A1 (fr) * 2003-04-18 2004-11-04 The Trustees Of The University Of Pennsylvania Compositions et methodes d'inhibition par arnic de l'angiopoietine 1 et 2 et de leur recepteur tie2
US7807814B2 (en) * 2003-12-23 2010-10-05 The Trustees Of The University Of Pennsylvania Compositions and methods for combined therapy of disease

Also Published As

Publication number Publication date
JP2010532662A (ja) 2010-10-14
EP2170351A4 (fr) 2011-07-06
WO2009008990A2 (fr) 2009-01-15
EP2170351A2 (fr) 2010-04-07
CN101959521A (zh) 2011-01-26
WO2009008990A3 (fr) 2009-06-04
US20110015249A1 (en) 2011-01-20

Similar Documents

Publication Publication Date Title
US20110015249A1 (en) Methods and compositions for treatment of cancer and other angiogenesis-related diseases
US9266947B2 (en) Inhibition of AXL signaling in anti-metastatic therapy
KR101867414B1 (ko) 호흡기 질환 연관 유전자 특이적 siRNA, 그러한 siRNA를 포함하는 이중나선 올리고 RNA 구조체 및 이를 포함하는 호흡기 질환 예방 또는 치료용 조성물
Kim et al. Anti-angiogenic inhibition of tumor growth by systemic delivery of PEI-g-PEG-RGD/pCMV-sFlt-1 complexes in tumor-bearing mice
US9074192B2 (en) Inhibition of AXL signaling in anti-metastatic therapy
EP3646887A1 (fr) Conjugué de protéine de vegf-grab et de médicament, et son utilisation
KR20080041145A (ko) 암 및 다른 신생혈관증식 질환을 치료하기 위한 ＲＮＡｉ치료제의 조성물 및 방법
WO2009151539A1 (fr) Compositions et procédés utilisant des molécules d’arnsi pour le traitement de gliomes
KR20120048613A (ko) Ｓｐａｒｃ 안티센스 조성물과 이들의 용도
Polyak et al. Systemic delivery of siRNA by aminated poly (α) glutamate for the treatment of solid tumors
JP2011500023A (ja) インビトロ及びインビボでＶＥＧＦＲ１発現を低減するための治療用ｓｉＲＮＡ分子
WO2014035828A2 (fr) Inhibition de la signalisation axl dans une thérapie anti-métastasique
IL310193A (en) Preparation and use of siRNA against VEGFR2 and TGF-beta 1 in combination in cancer treatment
CN115919888A (zh) 一种用于治疗多种肿瘤的核酸干扰药物组合物
US20130209542A1 (en) Pharmaceutical carrier and pharmaceutical composition for inhibiting angiogenesis

Legal Events

Date Code Title Description
FZDE Dead